Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ABC
ABcann Global
C$0.00
C$0.00
C$0.00
N/AN/AN/AN/A
Integer Holdings Co. stock logo
ITGR
Integer
$111.27
+1.2%
$114.24
$69.40
$123.99
$3.73B1.12511,895 shs224,856 shs
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
$6.66
+2.0%
$6.44
$4.74
$9.59
$2.55B1.29956,329 shs1.33 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$11.39
+1.3%
$10.89
$8.06
$13.24
$9.18B1.34.58 million shs3.69 million shs
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$18.44
$18.12
$5.80
$20.96
$1.94B2.081.87 million shs8 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Integer Holdings Co. stock logo
ITGR
Integer
+1.23%+1.53%-4.23%+7.08%+36.78%
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
+1.99%+7.42%+10.08%+10.82%-17.37%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+1.33%+3.26%-1.04%+15.17%+34.95%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ABC
ABcann Global
N/AN/AN/AN/AN/AN/AN/AN/A
Integer Holdings Co. stock logo
ITGR
Integer
1.9118 of 5 stars
1.31.00.00.03.72.53.1
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
1.8419 of 5 stars
3.12.00.00.02.32.50.6
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
3.6251 of 5 stars
4.51.00.00.02.52.51.9
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ABC
ABcann Global
N/AN/AN/AN/A
Integer Holdings Co. stock logo
ITGR
Integer
2.67
Moderate Buy$120.508.30% Upside
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
2.17
Hold$8.8332.63% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.90
Moderate Buy$16.9048.38% Upside
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/A

Current Analyst Ratings

Latest ROIV, ABC, LFST, ITGR, and TRIL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/26/2024
Integer Holdings Co. stock logo
ITGR
Integer
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$130.00
4/22/2024
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$10.00 ➝ $10.00
4/22/2024
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
4/15/2024
Integer Holdings Co. stock logo
ITGR
Integer
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$105.00 ➝ $135.00
4/9/2024
Integer Holdings Co. stock logo
ITGR
Integer
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$123.00 ➝ $139.00
4/3/2024
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$16.00 ➝ $18.00
4/3/2024
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$14.00 ➝ $15.00
4/3/2024
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$17.00 ➝ $18.00
3/28/2024
Integer Holdings Co. stock logo
ITGR
Integer
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$105.00 ➝ $130.00
3/25/2024
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00
3/14/2024
Integer Holdings Co. stock logo
ITGR
Integer
CL King
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$137.00
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ABC
ABcann Global
N/AN/AN/AN/AN/AN/A
Integer Holdings Co. stock logo
ITGR
Integer
$1.60B2.33$8.04 per share13.84$45.52 per share2.44
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
$1.06B2.41N/AN/A$3.77 per share1.77
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$61.28M149.78N/AN/A$2.11 per share5.40
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$150K12,907.39N/AN/A$2.56 per share7.20

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ABC
ABcann Global
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Integer Holdings Co. stock logo
ITGR
Integer
$90.65M$2.8938.5018.121.636.01%11.25%5.69%7/25/2024 (Estimated)
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
-$186.26M-$0.51N/AN/AN/A-17.64%-12.66%-8.65%5/9/2024 (Confirmed)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$1.01B$5.202.19N/AN/A3,624.14%-33.38%-26.06%6/26/2024 (Estimated)
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/A

Latest ROIV, ABC, LFST, ITGR, and TRIL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
-$0.09N/A+$0.09N/AN/AN/A  
4/25/2024Q1 2024
Integer Holdings Co. stock logo
ITGR
Integer
$1.12$1.14+$0.02$1.69$412.78 million$414.80 million      
2/28/2024Q4 2023
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
-$0.09-$0.12-$0.03-$0.12$263.14 million$280.60 million
2/15/2024Q4 2023
Integer Holdings Co. stock logo
ITGR
Integer
$1.34$1.39+$0.05$2.00$409.04 million$413.15 million    
2/13/2024Q3 2024
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.33-$0.26+$0.07-$6.55$30.72 million$37.14 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ABC
ABcann Global
N/AN/AN/AN/AN/A
Integer Holdings Co. stock logo
ITGR
Integer
N/AN/AN/AN/AN/A
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ABC
ABcann Global
N/AN/AN/A
Integer Holdings Co. stock logo
ITGR
Integer
0.76
3.32
2.01
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
0.20
1.11
1.11
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
0.06
27.79
27.79
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/A
19.82
19.82

Ownership

Institutional Ownership

CompanyInstitutional Ownership
ABC
ABcann Global
N/A
Integer Holdings Co. stock logo
ITGR
Integer
99.29%
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
85.50%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
87.15%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
ABC
ABcann Global
N/AN/AN/ANot Optionable
Integer Holdings Co. stock logo
ITGR
Integer
10,50033.50 million32.83 millionOptionable
LifeStance Health Group, Inc. stock logo
LFST
LifeStance Health Group
9,325382.24 million349.75 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
904805.85 million768.78 millionOptionable
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
33105.00 million95.44 millionOptionable

ROIV, ABC, LFST, ITGR, and TRIL Headlines

SourceHeadline
Cachet Bicycle shakes off COVIDCachet Bicycle shakes off COVID
baytoday.ca - February 25 at 12:23 PM
Rejuvenate your look with a trip to Fourth Avenue Medical AestheticsRejuvenate your look with a trip to Fourth Avenue Medical Aesthetics
chch.com - January 30 at 5:32 PM
TTI apprehends motorists for illegal removal of clamps, hunt for four others underwayTTI apprehends motorists for illegal removal of clamps, hunt for four others underway
bulawayo24.com - January 30 at 5:32 PM
BridgeBio raises $1.25bn, and other biotech financingsBridgeBio raises $1.25bn, and other biotech financings
pharmaphorum.com - January 19 at 7:18 AM
Ratio Therapeutics Raises $50M in Series B FinancingRatio Therapeutics Raises $50M in Series B Financing
precisionmedicineonline.com - January 17 at 1:39 PM
Leiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.comLeiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.com
businesswire.com - November 10 at 1:22 PM
Mirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, PredictionsMirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, Predictions
benzinga.com - November 8 at 1:30 AM
The Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast periodThe Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast period
uk.finance.yahoo.com - July 31 at 9:03 AM
Ratio Therapeutics unveils new research and development facilityRatio Therapeutics unveils new research and development facility
biopharma-reporter.com - May 15 at 10:33 AM
WHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: Can Cause Even DeathWHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death'
msn.com - April 26 at 12:18 AM
Leukemia Therapeutics Global Market Report 2023Leukemia Therapeutics Global Market Report 2023
uk.finance.yahoo.com - April 4 at 10:35 AM
Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with MerckRatio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck
finance.yahoo.com - March 28 at 9:12 AM
Trillium House, an affordable housing project in Warrenton, close to completionTrillium House, an affordable housing project in Warrenton, close to completion
dailyastorian.com - January 10 at 12:26 AM
FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular CarcinomaFDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma
nz.finance.yahoo.com - October 19 at 9:39 AM
Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer TreatmentCardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
seekingalpha.com - September 14 at 9:48 AM
Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of DirectorsZentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors
nz.finance.yahoo.com - September 12 at 7:55 AM
Pfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is NeededPfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is Needed
seekingalpha.com - August 17 at 11:07 AM
TTI reviews parking modelTTI reviews parking model
chronicle.co.zw - August 10 at 10:41 PM
TTI working round the clock to configure its systemsTTI working round the clock to configure its systems
chronicle.co.zw - August 10 at 10:41 PM
Pfizer in advanced talks to buy firm making sickle cell drugsPfizer in advanced talks to buy firm making sickle cell drugs
pmnewsnigeria.com - August 7 at 3:57 AM
10 Psychedelics CEOs To Pay Attention To In 202210 Psychedelics CEOs To Pay Attention To In 2022
markets.businessinsider.com - June 22 at 10:08 AM
Highlights from ASCO Annual Meeting 2022Highlights from ASCO Annual Meeting 2022
healio.com - June 15 at 1:37 PM
Chlormethine gel may be more effective than ointment for mycosis fungoidesChlormethine gel may be more effective than ointment for mycosis fungoides
healio.com - May 27 at 4:34 PM
Pfizer and Moderna created life-saving vaccines. So why are their stocks crumbling?Pfizer and Moderna created life-saving vaccines. So why are their stocks crumbling?
edition.cnn.com - May 20 at 2:06 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

ABcann Global

CVE:ABC
Integer logo

Integer

NYSE:ITGR
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
LifeStance Health Group logo

LifeStance Health Group

NASDAQ:LFST
LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.
Roivant Sciences logo

Roivant Sciences

NASDAQ:ROIV
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
Trillium Therapeutics logo

Trillium Therapeutics

NASDAQ:TRIL
Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.